Participants not approved by the national treatment guideline or the Interferon Committee for combined pegylated interferon-ribavirin treatment

Contraindications in the summary of product characteristics of pegylated interferon alpha-2a and ribavirin

Participants previously treated with pegylated interferon and/or ribavirin

Hepatitis B and Human Immunodeficiency Virus co-infections

An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C